Luc Sauriol scite author profile

Key MessagesIn clinical trials, Gla-300 had similar glycated hemoglobin (A1C) reduction and a lower risk of hypoglycemia than Gla-100 in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D). In a real-world clinical setting, insulin-naïve patients with T2D initiating Gla-300 or Gla-100 had similar A1C reduction and weight change.Patients with T1D or T2D switching to Gla-300 had significant reductions in A1C with no change in weight or insulin dose.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Luc Sauriol

Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada

Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study

Alzheimer's disease: a review of the disease, its epidemiology and economic impact

The Burden of Atrial Fibrillation on the Hospital Sector in Canada

Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study

Contact Info

Product

Resources

About